Bli medlem
Bli medlem

Du är här

2016-03-03

Oasmia Pharmaceutical Reissues Executive Summary

a Pharmaceutical Reissues Executive Summary

Uppsala, Sweden, 2016-02-29 22:05 CET (GLOBE NEWSWIRE) --

Uppsala, February 29, 2016 – On Friday, February 26, 2016, Oasmia
Pharmaceutical AB (“Oasmia”) inadvertently filed an incorrect version of its
Executive Summary with the Securities Exchange Commission (“SEC”) on a Form 6-K
that must be amended and restated. The version of the Executive Summary
misstated certain figures and therefore should not be relied upon. The correct
version of the Executive Summary will be filed with the SEC on an amendment to
the Form 6-K in conjunction with the issuance of this press release. Oasmia
strives to maintain full transparency with its shareholders as well as
regulatory bodies and will continue to do so.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of
human and veterinary oncology. The company’s product development aims to create
and manufacture novel nanoparticle formulations and drug-delivery systems based
on well-established cytostatics which, in comparison with current alternatives,
show improved properties, reduced side-effects, and expanded applications. The
company’s product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ Stockholm (OASM.ST), Frankfurt
Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Capital Markets
(OASM.US).

Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com

For media relations:
Eric Fischgrund
Founder
FischTank
Tel: +1 (646) 699 1414
E-mail: eric@fischtankpr.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.